ZSAN Zosano Pharma Corporation

2.19
0  0%
Previous Close 2.19
Open 2.19
Price To Book 0.92
Market Cap 26220955
Shares 11,973,039
Volume 102,598
Short Ratio
Av. Daily Volume 113,751

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
M207
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia
12-mth safety data 1Q 2019.
M207-ADAM
Migraine

SEC Filings

  1. 8-K - Current report 19528316
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19509135
  3. CT ORDER - Confidential treatment order 181244874
  4. NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB 181187604
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181185968
  6. 8-K - Current report 181183910
  7. 8-K - Current report 181123573
  8. 8-K - Current report 181103728
  9. 8-K - Current report 181086908
  10. 8-K - Current report 181083880